Related Experiment Video

Updated: Nov 26, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.6K

Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases

Maan H Harbi1, Christopher W Smith1, Phillip L R Nicolson1,2

  • 1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham , Birmingham, UK.

Platelets
|December 14, 2020
PubMed

Insights

Targeting platelet receptors GPVI and CLEC-2 offers a novel approach to treating arterial thrombosis. Inhibiting these receptors may enhance antithrombotic efficacy with reduced bleeding risk compared to current therapies.

Area of Science:

  • Cardiovascular Research
  • Hematology
  • Pharmacology

Background:

  • Antiplatelet medications are crucial for arterial thrombosis but can cause bleeding and treatment failure.
  • Platelet activation via collagen-GPVI interaction is key in atherosclerotic plaque rupture and thrombosis.
  • GPVI deficiency shows minimal bleeding impact, suggesting therapeutic potential.

Purpose of the Study:

  • To review the role of GPVI and CLEC-2 in arterial thrombosis.
  • To explore strategies for inhibiting GPVI and CLEC-2 as novel antithrombotic treatments.
  • To evaluate the potential for reduced bleeding complications compared to conventional antiplatelet drugs.

Main Methods:

  • Review of existing scientific literature on GPVI, CLEC-2, and antiplatelet therapies.
  • Analysis of signaling pathways involving Src, Syk, and Tec family tyrosine kinases.
  • Evaluation of the pathophysiological role of platelet receptors in thrombosis.

Main Results:

  • GPVI and CLEC-2 are significant targets for inhibiting platelet recruitment and activation.
  • Targeting GPVI and CLEC-2 may offer improved antithrombotic effects with less impact on hemostasis.
  • Inhibition of downstream signaling kinases presents an alternative therapeutic strategy.

Conclusions:

  • Targeting GPVI and CLEC-2 represents a promising therapeutic strategy for arterial thrombosis.
  • Inhibiting these receptors could provide enhanced antithrombotic efficacy with a favorable safety profile.
  • Further research into GPVI and CLEC-2 inhibition is warranted for novel thrombo-inflammatory disorder treatments.

Keywords:
BtkCLEC-2GPVIantiplatelettyrosine kinase

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

940
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.3K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
878
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
322
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.8K